Legacy Financial Advisors Inc. Raises Stock Holdings in AstraZeneca PLC $AZN

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Legacy Financial Advisors Inc. grew its position in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 65.9% in the first quarter, according to its most recent filing with the SEC. The fund owned 11,736 shares of the company's stock after acquiring an additional 4,663 shares during the quarter. Legacy Financial Advisors Inc.'s holdings in AstraZeneca were worth $863,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Dynamic Advisor Solutions LLC raised its holdings in AstraZeneca by 58.4% during the 1st quarter. Dynamic Advisor Solutions LLC now owns 13,055 shares of the company's stock valued at $960,000 after buying an additional 4,811 shares during the period. Farther Finance Advisors LLC raised its holdings in AstraZeneca by 13.1% during the 1st quarter. Farther Finance Advisors LLC now owns 6,083 shares of the company's stock valued at $442,000 after buying an additional 706 shares during the period. Wealth Enhancement Advisory Services LLC raised its holdings in AstraZeneca by 1.8% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 311,600 shares of the company's stock valued at $22,903,000 after buying an additional 5,557 shares during the period. Schonfeld Strategic Advisors LLC raised its holdings in AstraZeneca by 74.5% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 36,300 shares of the company's stock valued at $2,378,000 after buying an additional 15,499 shares during the period. Finally, Vontobel Holding Ltd. purchased a new stake in AstraZeneca during the 1st quarter valued at $727,000. Hedge funds and other institutional investors own 20.35% of the company's stock.

AstraZeneca Trading Up 0.6%

AstraZeneca stock traded up $0.51 during mid-day trading on Friday, hitting $80.97. The company's stock had a trading volume of 3,603,793 shares, compared to its average volume of 5,320,253. The company has a 50 day moving average of $72.93 and a 200-day moving average of $72.25. The stock has a market cap of $251.12 billion, a PE ratio of 30.44, a P/E/G ratio of 1.49 and a beta of 0.36. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.67 and a current ratio of 0.86. AstraZeneca PLC has a one year low of $61.24 and a one year high of $87.68.

AstraZeneca (NASDAQ:AZN - Get Free Report) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $1.09 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $1.09. AstraZeneca had a return on equity of 32.84% and a net margin of 14.68%.The business had revenue of $14.46 billion for the quarter, compared to the consensus estimate of $14.08 billion. During the same quarter in the prior year, the company earned $1.24 EPS. The business's revenue was up 16.1% compared to the same quarter last year. On average, research analysts anticipate that AstraZeneca PLC will post 4.51 EPS for the current year.

AstraZeneca Cuts Dividend

The company also recently declared a semi-annual dividend, which will be paid on Monday, September 8th. Stockholders of record on Friday, August 8th will be given a dividend of $0.505 per share. The ex-dividend date of this dividend is Friday, August 8th. This represents a dividend yield of 200.0%. AstraZeneca's dividend payout ratio is presently 37.97%.

Analyst Upgrades and Downgrades

Separately, Berenberg Bank set a $97.00 price target on AstraZeneca in a report on Wednesday, July 9th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $86.00.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.